Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434990 | 0.81 | MAPT (0.56) | MAPTKDM4EGAAALDH1A1HPGD | |
| SCHEMBL14875659 | 0.80 | GAA (0.43) | MAPTKDM4EGAAALDH1A1HPGD | |
| SCHEMBL14875393 | 0.76 | MAPT (0.54) | MAPTKDM4EGAAALDH1A1HPGD | |
| SCHEMBL2463999 | 0.74 | KDM4E (0.57) | MAPTKDM4EGAAALDH1A1KCNH2 | |
| SCHEMBL2434998 | 0.71 | GAA (0.47) | MAPTKDM4EGAAALDH1A1HPGD | |
| SCHEMBL14875394 | 0.67 | GAA (0.46) | MAPTKDM4EGAAALDH1A1HPGD | |
| SCHEMBL14875788 | 0.67 | GAA (0.64) | MAPTKDM4EGAAALDH1A1HPGD | |
| SCHEMBL14875576 | 0.67 | GAA (0.53) | MAPTKDM4EGAAALDH1A1HPGD | |
| SCHEMBL2464004 | 0.65 | GRIA1 (0.47) | MAPTKDM4EGAAALDH1A1ALOX5 | |
| SCHEMBL1921879 | 0.64 | BTK (0.44) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | claimed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-9227967-B2 | Inhibitor compounds of semicarbazide-sensitive amine oxidases | PROXIMAGEN LIMITED (GB) | 2016-01-05 | — | — | US | disclosed |
| EP-2927233-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | Proximagen Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2547677-B1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE | PROXIMAGEN LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | PROXIMAGEN LIMITED (GB) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | MAPT 3148/4885KDM4E 3168/4885GAA 10/4885 |
| US-20130102587-A1 | New Enzyme Inhibitor Compounds | SERPINB1, SSB, NFKBIA | MAPT 4230/4885KDM4E 2930/4885GAA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.